Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

2007 2006

(Unaudited)

Assets:

Current Assets:

Cash and cash equivalents $2,218,246 $559,017

Inventory, net of reserve for

obsolescence - 1,556

Prepaid expenses and

other current assets 74,484 12,994

Total current assets 2,292,730 573,567

Property and Equipment, at cost:

Computer equipment 248,272 245,694

Office and laboratory equipment 590,926 590,926

Furniture and fixtures 14,288 14,288

Manufacturing equipment 197,888 197,888

Leasehold improvements 177,768 177,768

1,229,142 1,226,564

Less-Accumulated depreciation and

amortization (1,105,441) (1,017,051)

Net property and equipment 123,701 209,513

Other Assets:

Restricted cash 10,250 19,949

Deposits and other assets 2,000 2,000

Intangible assets, net 10,420,000 -

Total other assets 10,432,250 21,949

Total assets $12,848,681 $805,029

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable $363,057 $45,817

Deferred revenue 8,333 45,833

Current portion of notes payable,

net of unamortized discount 55,208 89,808

Accrued expenses
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
(Date:5/23/2013)... 2013 Watlow®, an industry leader ... systems, recently introduced its new catalog, Watlow® Heating ... in designing and manufacturing industrial heaters, Watlow provides ... serve diverse customer needs. , A description of ... beginning of the book. These options allow high ...
Breaking Biology Technology:Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2
... Reaching First Clinical Milestone Validates Approach, SAN ... successful completion of its first clinical trial, a,proof-of-concept ... a sodium channel blocker. Rufinamide was discovered and,developed ... in Europe as a,drug to treat a form ...
... January 22 Arpida Ltd.,(SWX: ARPN) announced today that ... with the TLT treatment in onychomycosis has been,initiated and ... 220 patients in total will be enrolled in this ... interest to,participate well in advance of the trial., ...
... nation,s top-10 GPOs(1), IRVINE, Calif., Jan. ... and Read-Through Motion and Low Perfusion pulse,oximetry, ... supplier agreement,with HealthTrust Purchasing Group (HealthTrust), representing ... ambulatory surgery,centers, alternate care sites and physician ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 2Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 3Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis 4Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 2Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 3Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 4
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
(Date:5/22/2013)... important new details on how climate change will affect ... in the Journal of Animal Ecology . This ... and informing policymakers of how species are likely to ... is a growing recognition among biologists that climate change ... that this is going to have very important consequences ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... this year, says the American Cancer Society, and 10,000 ... in the early stages, melanoma can be a particularly ... an efficiency that few tumors possess. Now, researchers at ... the reasons why this particular skin tumor is so ...
... Hopkins have discovered the presence of functional ion channels ... act like electrical wires and permit ESCs, versatile cells ... types of the body, to conduct and pass along ... of these channels in implanted cells, derived from stem ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
Cached Biology News:Researchers discover why melanoma is so malignant 2Researchers discover why melanoma is so malignant 3Stem cells' electric abilities might help their safe clinical use 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
...
...
Biology Products: